eContour
BR
Cardiac contouring atlas [ OAR ]

CT-based contouring atlas
BR
Partial Breast Irradiation (PBI) [ 3DCRT technique at MSKCC ]

T1N0 ER+
BR
Partial Breast Irradiation (PBI) [ IMRT technique per Florence Trial ]

T1N0 ER+
BR
Post-mastectomy radiation (PMRT) [ neoadjuvant chemo ]

IIIC (cT3N3bM0)
BR
Post-Mastectomy Radiation (PMRT) [ RTCHARM Trial ]

hypofractionation
BR
Regional Nodal Irradiation [ RNI ]

IIB (pT2N1M0)
BR
Whole breast [ 26Gy/5 per UK FAST Forward ]

ultra-hypofractionation
BR
Whole Breast [ IMRT with SIB per RTOG 1005 ]

hypofractionation with SIB
BR
Whole breast [ L-sided DIBH and heart block ]

hypofractionation
CNS
Glioblastoma Multiforme [ GBM ]

unresectable
CNS
Intact Brain Metastases [ SRS ]

IV
CNS
Low Grade Glioma [ LGG ]

high risk
CNS
Meningioma [ grade II atypical ]

benign
CNS
Pituitary Adenoma [ recurrent ]

benign
CNS
Vestibular Schwannoma [ formerly Acoustic Neuroma ]

benign
GI
anal [ definitive ]

IIIA (cT2N1M0)
GI
Esophageal [ GEJ (pre-op) ]

IIIA (uT3N1M0)
GI
Esophageal [ Upper Esophagus SCC ]

III (cT3N0M0)
GI
Gastric [ Neoadjuvant technique per TOPGEAR ]

III (cT3N2M0)
GI
HCC [ SBRT ]

Child Pugh A
GI
Organs at Risk [ OAR ]

Upper Abdominal MRI-based (T1)
GI
Organs at Risk [ OAR ]

Upper Abdominal MRI-based (T2)
GI
pancreas [ post-op ]

IIB (pT3N1M0)
GI
Rectal [ pre-op ]

IIIA (uT2N1M0)
GI
Rectal [ RAPIDO Trial ]

hypofractionation
GU
bladder [ preservation ]

II (T2bN0M0)
GU
prostate [ intact ]

conventional fractionation
GU
prostate [ intact ]

hypofractionation
GU
prostate [ post-prostatectomy ]

III (pT3aN0M0)
GU
testicular [ dog-leg ]

IIA (T1N1M0S1)
GYN
cervical [ intact ] NRG

FIGO IIB
GYN
Cervical [ post-op (pelvis alone) ]

FIGO IB1
GYN
Cervical Cancer [ EMBRACE 2 ]

IIB
GYN
Endometrial [ post-op (pelvis alone) ]

FIGO IB (G3)
GYN
Endometrial [ post-op (VB alone) ]

FIGO IB (G2)
GYN
Endometrial [ salvage SBRT ]

PA nodal recurrence
GYN
palliation [ quad shot ]

IV
GYN
Vaginal [ definitive ]

FIGO II (T2N1M0)
HN
Cutaneous Squamous Cell Carcinoma [ CN V1 tracing ]

II (T2N0M0)
HN
hypopharynx [ pyriform sinus ]

IVA (T4aN0M0)
HN
larynx [ early-stage glottic ]

I (T2N0M0)
HN
Larynx [ subglottic ]

I (T1N0M0)
HN
larynx [ supraglottic ]

IVA (T3N2cM0)
HN
nasopharynx [ NPX ]

III (T2N2M0)
HN
Oral cavity [ buccal mucosa ]

IVA (pT4N0M0)
HN
oral cavity [ tongue ]

II (pT2N0M0)
HN
Organs At Risk [ OARs ]

DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG Consensus Guidelines
HN
Oropharynx [ BOT ]

IVA (T3N2cM0)
HN
oropharynx [ tonsil-unilateral RT ]

I (cT2N0M0)
HN
Paranasal sinus [ maxillary ]

III (pT3N0M0)
HN
salivary gland [ adenoid cystic of hard palate (V2) ]

IVA (pT4N0M0)
HN
salivary gland [ parotid-tracing CNVII ]

III (pT3N0M0)
HN
thyroid [ medullary ]

recurrent
HN
unknown primary [ p16- smoker ]

IVA (TxN2bM0)
LU
NSCLC [ central lung SBRT ]

IA2
LU
NSCLC [ PORT ]

pN2
LU
NSCLC [ single-fraction SBRT ]
LYMPH
Hodgkin [ early-stage favorable ]

IIA
LYMPH
Hodgkin [ early-stage unfavorable ]

IIAX
LYMPH
Hodgkin [ NLPHL (axillary node) ]

IA
LYMPH
NHL [ follicular (inguinal node) ]

IA
LYMPH
NHL [ Gastric DLBCL ] ILROG

I
LYMPH
NHL [ MALT (conjunctiva) ]

IE
LYMPH
NHL [ MALT (lacrimal gland) ]

IE
LYMPH
NHL [ MALT (parotid) ]

IV
SARC
Lower extremity [ Post-operative ]

IIIA (pT2N0G2)
SARC
Lower extremity [ Pre-operative ]

IIIB (cT3N0M0)
SARC
Retroperitoneal [ Pre-operative ]

IIIB (cT3N0G3)